2076 related articles for article (PubMed ID: 21406297)
1. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
2. Control of hyperphosphatemia among patients with ESRD.
Coladonato JA
J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
[TBL] [Abstract][Full Text] [Related]
3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
4. Management of phosphorus load in CKD patients.
Taketani Y; Koiwa F; Yokoyama K
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
[TBL] [Abstract][Full Text] [Related]
5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
7. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of phosphorus retention in chronic kidney disease: a review.
Amiri FS
Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
[TBL] [Abstract][Full Text] [Related]
9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
Martin KJ; González EA
Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
[TBL] [Abstract][Full Text] [Related]
10. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
11. Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease.
Adema AY; de Borst MH; Ter Wee PM; Vervloet MG;
J Ren Nutr; 2014 May; 24(3):143-50. PubMed ID: 24216259
[TBL] [Abstract][Full Text] [Related]
12. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
13. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
14. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
Hruska KA; Mathew S
Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
[TBL] [Abstract][Full Text] [Related]
15. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
Kestenbaum B
Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
17. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers.
Larsson T; Nisbeth U; Ljunggren O; Jüppner H; Jonsson KB
Kidney Int; 2003 Dec; 64(6):2272-9. PubMed ID: 14633152
[TBL] [Abstract][Full Text] [Related]
18. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
Dhillon-Jhattu S; Sprague SM
Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
[TBL] [Abstract][Full Text] [Related]
19. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
20. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]